What happened to Vascepa's patents and how did generic competition impact Amarin?

Vascepa's commercial trajectory was severely impaired by patent litigation. Amarin patented Vascepa's use for CV risk reduction (the REDUCE-IT indication) and tried to maintain exclusivity through multiple patent claims. In 2020, a U.S. District Court in Nevada ruled against Amarin's patents — finding that claims related to using EPA to reduce cardiovascular risk were invalid (obvious to a person skilled in the art). This decision was devastating: generic manufacturers were permitted to launch generic icosapentaenoic acid products in the U.S. at dramatically lower prices. Amarin appealed, but the Federal Circuit upheld the district court ruling. The impact was severe: branded Vascepa's U.S. market share collapsed from ~100% (pre-generic) to a small fraction; U.S. revenue fell from approximately $600M annually to a fraction; Amarin's stock price fell >80% from peak. Without patent protection, Amarin effectively lost its core U.S. market just as the cardiovascular indication was gaining traction. Amarin pivoted to Europe (where patents are still in effect) as its primary growth market.

What is mobile health and what differentiates Docgo from traditional healthcare delivery?

Traditional healthcare delivery is clinic-centric — patients must travel to a doctor's office, urgent care center, or hospital to receive care. Mobile health reverses this model by bringing care to where the patient is: at home, at their workplace, in their community, or at a care site managed by Docgo. Docgo's mobile health platform deploys vehicles equipped with clinical supplies (point-of-care diagnostics, vaccines, telehealth connectivity) staffed by paramedics, EMTs, nurses, and physician extenders. Services include: preventive screenings (blood pressure, diabetes, cholesterol); chronic disease management visits; vaccinations and immunizations; wound care; behavioral health assessments; medication management; and acute care for lower-acuity conditions. Mobile health addresses barriers to traditional care: transportation challenges for elderly or low-income patients; time constraints for working patients; underserved geographic areas without nearby clinics; and employer workplace wellness programs. The model is most cost-effective for preventive care and chronic disease management that doesn't require hospital or specialty equipment.

What is the difference between a prescription omega-3 fish oil like Vascepa and over-the-counter fish oil supplements?

There are three categories of omega-3 products: Prescription omega-3 fatty acids — FDA-regulated pharmaceutical products with defined composition, purity, and efficacy data. Vascepa contains 96%+ pure EPA (eicosapentaenoic acid) with minimal DHA; approved at 4g/day for both high triglycerides and cardiovascular risk reduction based on clinical trials. Other Rx omega-3s (Lovaza, Epanova) contain both EPA and DHA. Omega-3 prescription drugs are manufactured under pharmaceutical GMP standards with rigorous quality control. OTC fish oil supplements — dietary supplements regulated as foods, not drugs; no FDA approval required; variable EPA/DHA content (often lower doses, inconsistent purity); limited required evidence of efficacy. A typical OTC fish oil capsule contains 300-600mg of combined EPA+DHA in a 1g capsule; achieving Vascepa's 4g/day EPA dose would require 7-14 standard OTC capsules and still wouldn't deliver pure EPA. Clinical evidence — the REDUCE-IT data is specific to pharmaceutical-grade pure EPA at 4g/day; it cannot be extrapolated to assume OTC fish oil supplements provide the same cardiovascular benefit; in fact, some trials of combined EPA+DHA supplements showed no cardiovascular benefit in statin-treated patients.

brimindinvest.com / compare / amrn-vs-dcgoLIVE

AMRN

Amarin Corporation plc · Healthcare - Specialty Pharmaceuticals

$16.03

+14.09% this month

VERSUS

⟷

COMPARE

DCGO

Docgo Inc. · Healthcare - Mobile Health Services

$0.52

-7.58% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

AMRN

2

DCGO

2

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

AMRN ✓24.0

DCGO 22.7

1Y Return

AMRN ✓+20.26%

DCGO -67.65%

Fwd P/E

AMRN 16.36

DCGO ✓2.80

Target Up.

AMRN -22.02%

DCGO ✓+258.15%

Op. Margin

AMRN N/A

DCGO N/A

Metrics last refreshed: 6/20/2026

Quick take

AMRN vs DCGO Stock Comparison: AI Score, Valuation, Performance and Upside

AMRN (Amarin) and DCGO (Docgo) are both smaller healthcare companies addressing real medical needs but with very different business models — Amarin is a pharma company with breakthrough cardiovascular clinical data from REDUCE-IT but a severely impaired commercial position from generic competition, while Docgo is a mobile health services company growing through government and employer contracts to bring care to patients in non-traditional settings. Both are higher-risk investments where execution and external factors (patent courts, government contracts) significantly affect outcomes.

AMRN vs DCGO is specialty pharma with landmark cardiovascular clinical data but commercial challenges from generics (Amarin's Vascepa/Vazkepa 25% MACE reduction in REDUCE-IT seeking to rebuild revenue through European market launch and physician retention of the branded cardiovascular story) versus mobile health services company growing through government and employer care delivery contracts (Docgo's fleet-based clinical care model serving underserved populations and employers with episodic high-value government contracts) — pharma rebuilding after generic disruption versus mobile health services with contract-driven growth.

Live analysis · updated 6/20/2026

AMRN and DCGO are closely matched — they split the tracked metrics evenly. AMRN has delivered stronger 1-year price return (+20.26% vs -67.65%), though DCGO trades at the lower forward P/E (2.80x vs 16.36x). Analyst consensus implies meaningfully more upside for DCGO (+258.15%) than for AMRN (-22.02%).

Normalized 1Y performance

AMRN

DCGO

Recent returns

AMRN

DCGO

Analyst price targets & sentiment

AMRN · 2 analysts

Price target range

analyst low$12.00
analyst high$13.00
analyst mean$12.50
current price$16.03

-22.0% upside to analyst mean

DCGO · 4 analysts

Price target range

analyst low$1.00
analyst high$3.00
analyst mean$1.88
current price$0.52

+258.1% upside to analyst mean

Who should consider this stock?

AMRN may suit investors who:

→Believe Amarin's European commercial launch of Vazkepa can generate significant revenue from markets where generic competition hasn't yet eroded the branded cardiovascular risk reduction market as in the U.S.
→Value the scientific strength of the REDUCE-IT cardiovascular outcomes data as supporting long-term physician preference for the pure EPA approach, creating a base of loyal prescribers even in generic competition environments
→Evaluate Amarin as a potential acquisition target for a larger cardiovascular pharmaceutical company that could leverage the REDUCE-IT data globally and provide commercial infrastructure Amarin lacks

DCGO may suit investors who:

→Believe mobile health services represent a structurally growing market as employers and governments seek cost-effective ways to deliver care outside traditional clinic settings
→See Docgo's government contract track record as demonstrating the ability to execute mobile health programs at scale, with potential for more durable long-term enterprise and government contracts
→Accept the higher risk profile of a small, pre-profitability mobile health company in exchange for potential upside if mobile health services achieve mainstream adoption in employer wellness and government health programs

Performance & AI score

Metric	AMRN	DCGO
AI score	24.0	22.7
AI rank	#3312	#3953
Latest close	$16.03	$0.52
1M return	+14.09%	-7.58%
6M return	+16.75%	-44.31%
1Y return	+20.26%	-67.65%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	AMRN	DCGO
1Y ago	$12.03K (+20.3%) started 2025-06-18	$3.23K (-67.7%) started 2025-06-18
5Y ago	$1.62K (-83.8%) started 2021-06-18	$526.05 (-94.7%) started 2021-06-18
10Y ago	$3.82K (-61.8%) started 2016-06-20	$508.74 (-94.9%) started 2020-12-17

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	AMRN	DCGO
Market cap	$336.13M	$51.72M
Trailing P/E	N/A	N/A
Forward P/E	16.36	2.80
Price/Sales	1.55	0.17
EV/Revenue	0.08	0.10
Analyst target	$12.50	$1.88
Target upside	-22.02%	+258.15%

Growth, profitability & risk

Metric	AMRN	DCGO
Revenue growth	7.40%	-21.30%
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	+1.03%	+14.58%
Operating margin	N/A	N/A
Profit margin	-15.51%	-62.23%
ROIC proxy	-7.28%	-97.78%
Return on equity	-7.28%	-97.78%
Dividend yield	0.00%	0.00%
Beta	0.82	1.00
Debt/equity	1.71	25.63
Current ratio	3.48	1.79
Quick ratio	2.31	1.68

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

AMRN max drawdown33.33%

DCGO max drawdown69.94%

AMRN max wkly drop19.75%

DCGO max wkly drop23.49%

5Y risk snapshot

AMRN max drawdown93.15%

DCGO max drawdown95.32%

AMRN max wkly drop54.01%

DCGO max wkly drop41.67%

10Y risk snapshot

AMRN max drawdown98.34%

DCGO max drawdown95.32%

AMRN max wkly drop66.41%

DCGO max wkly drop41.67%

Performance metrics by period

Period	Metric	AMRN	DCGO
1Y	Growth	+20.26%	-67.65%
	CAGR	+20.27%	-67.68%
	Sharpe ratio	0.52	-1.17
	Max drawdown	33.33%	69.94%
	Max daily drop	11.25%	14.77%
	Max wkly drop	19.75%	23.49%
5Y	Growth	-83.84%	-94.74%
	CAGR	-30.55%	-44.52%
	Sharpe ratio	-0.23	-0.57
	Max drawdown	93.15%	95.32%
	Max daily drop	43.07%	39.91%
	Max wkly drop	54.01%	41.67%
10Y	Growth	-61.83%	-94.91%
	CAGR	-9.19%	-41.81%
	Sharpe ratio	0.25	-0.56
	Max drawdown	98.34%	95.32%
	Max daily drop	70.54%	39.91%
	Max wkly drop	66.41%	41.67%

Business comparison

Category	AMRN	DCGO
Company	Amarin Corporation plc	Docgo Inc.
Sector	Healthcare - Specialty Pharmaceuticals	Healthcare - Mobile Health Services
Industry	N/A	N/A
Core business	Amarin is a specialty pharmaceutical company with its primary product Vascepa (icosapentaenoic acid, or EPA) — a pure EPA omega-3 fish oil prescription drug approved for severe hypertriglyceridemia (high triglycerides, the SH indication) and, following the landmark REDUCE-IT trial, for cardiovascular risk reduction in patients already on statins. The REDUCE-IT trial showed Vascepa reduced major adverse cardiovascular events by 25% versus placebo in patients with elevated triglycerides on statin therapy — one of the most significant cardiovascular outcomes trial results in a decade. However, patent battles with generic manufacturers significantly impaired Vascepa's commercial trajectory.	Docgo provides mobile health services through a fleet of medical vehicles and telehealth capabilities — deploying teams of paramedics, EMTs, and nurses to bring clinical care directly to patients in their homes, workplaces, and communities. Docgo's services include mobile primary care visits, chronic disease management, preventive screenings, COVID-19 testing and vaccination, and migrant health services. Docgo operates in multiple U.S. cities and international markets, often under government and employer contracts.
Investor focus	Investors track Vascepa's U.S. prescription volume (severely impacted by generic competition after patent loss), the European market launch (Vazkepa in the EU and UK under different brand name for the CV risk indication), remaining patent protection, and whether Amarin can generate sufficient revenue to remain viable.	Investors track Docgo's revenue growth (contract wins from governments and employers), gross margins on mobile health visits, contract sustainability (government migrant health services contracts have variable duration), and the long-term platform potential of mobile health as an alternative to traditional clinic-based care.

AMRN strengths

→REDUCE-IT trial produced remarkable cardiovascular outcomes data — a 25% reduction in MACE (major adverse cardiovascular events) in a large well-controlled trial represents one of the most significant cardiovascular outcomes results of the past decade; the biological mechanism of pure EPA omega-3 at high doses has strong scientific support
→European market provides new commercial opportunity — Vaskepa (EU brand) approval in Europe for CV risk reduction provides a market where generic competition has not yet fully eroded the branded drug premium; European cardiovascular care could be a meaningful revenue contributor
→Established cardiovascular physician relationships and prescriber awareness — Amarin's U.S. commercial infrastructure built prescriber awareness of Vascepa's CV risk data; some physicians continue prescribing branded Vascepa despite generic availability

DCGO strengths

→Mobile health meets patients where they are — Docgo's at-home and workplace care model reduces barriers to healthcare access; employers value on-site services reducing employee time away from work; underserved communities benefit from care delivery without transportation challenges
→Government contract revenue provides near-term revenue visibility — Docgo has won significant government contracts for migrant and refugee health services, providing multi-month contracted revenue; these contracts demonstrate Docgo's ability to execute at scale for government health programs
→Early mover in mobile clinical care services market — mobile health services beyond traditional emergency response are an emerging category; Docgo's experience deploying mobile clinical teams creates operational expertise in logistics, staffing, and care protocols that late entrants must develop from scratch

Risks to watch — AMRN

→Generic competition has dramatically reduced U.S. Vascepa revenue — after losing key patent challenges, generic icosapentaenoic acid products entered the U.S. market at dramatically lower prices; branded Vascepa's market share has been severely impacted
→European commercial launch execution and acceptance are uncertain — European cardiovascular guidelines adoption of EPA for CV risk reduction determines how broadly European cardiologists will prescribe Vazkepa; reimbursement decisions and formulary positions across European countries take years to resolve
→Company viability with limited revenue — Amarin's revenue has declined sharply with generic entry; the company must successfully monetize European sales or find strategic alternatives (partnership, acquisition, royalty arrangements) to remain financially viable

Risks to watch — DCGO

→Government migrant health contracts are politically sensitive and non-recurring — Docgo's government contracts for migrant health services (particularly NYC migrant health services) generated significant revenue but are episodic and subject to political changes and contract renewals
→Profitability challenges from mobile care model — mobile health services require significant staffing, vehicle, and logistics costs; achieving sustainable margins in a labor-intensive mobile model while maintaining quality care is operationally challenging
→Small company with limited scale and competitive clarity — Docgo operates in markets where the mobile health competitive landscape is fragmented; the company must demonstrate a clear path to scale and sustainable unit economics to justify investor confidence

Frequently asked questions

REDUCE-IT (Reduction of Cardiovascular Events with Icosapentaenoic Acid Intervention Trial) was a landmark 8,179-patient cardiovascular outcomes trial that tested high-dose Vascepa (4 grams/day of pure icosapentaenoic acid, EPA) in patients with elevated triglycerides already on statin therapy. The trial results (published 2018 in the New England Journal of Medicine) showed Vascepa reduced the primary endpoint — composite of cardiovascular death, nonfatal heart attack, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina — by 25% versus placebo. This was one of the largest cardiovascular risk reductions seen in a major trial since statin therapy itself. The mechanism debate: the placebo used in REDUCE-IT was mineral oil rather than an inert placebo, and critics argued mineral oil may have modestly raised LDL and other markers in the control arm, inflating the apparent benefit. The FDA approved Vascepa for the cardiovascular risk reduction indication in December 2019 based on REDUCE-IT, but the mineral oil controversy has created ongoing scientific debate about the magnitude of benefit.

AI Prediction SignalNext 5 trading days

Members only

AMRN

+2.8%BUY

DCGO

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides